Protection of normal brain cells from γ-irradiation-induced apoptosis by a mitochondria-targeted triphenyl-phosphonium-nitroxide: a possible utility in glioblastoma therapy

Glioblastoma multiforme is the most frequent and aggressive primary brain tumor. A strong rationale to identify innovative approaches to treat these tumors is required since treatment failures result in local recurrences and median survivals range from 9 to 12 months. Glioma cells are reported to have less mitochondrial content compared to adjacent normal brain cells. Based on this difference, we suggest a new strategy, utilizing protection of normal brain cells by mitochondria-targeted electron scavengers and antioxidants—nitroxides—thus allowing for the escalation of the radiation doses. In this paper, we report that a conjugate of nitroxide with a hydrophobic cation, triphenyl-phosphonium (TPEY-Tempo), significantly protected brain endothelial cells from γ-irradiation-induced apoptosis while radiosensitizing brain tumor cells. Thus, TPEY-Tempo may be a promising adjunct in the treatment of glioblastoma with the potential to not only prolong survival but also to maintain quality of life and reduce treatment toxicity.

[1]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[2]  D. Schoenfeld,et al.  Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study , 1983, Cancer.

[3]  S. Hahn,et al.  Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. , 1991, Archives of biochemistry and biophysics.

[4]  S. Hahn,et al.  Identification of nitroxide radioprotectors. , 1992, Radiation research.

[5]  S. Hahn,et al.  Tempol, a stable free radical, is a novel murine radiation protector. , 1992, Cancer research.

[6]  C C Ling,et al.  Radiation-induced apoptosis: relevance to radiotherapy. , 1995, International journal of radiation oncology, biology, physics.

[7]  R. Burdon Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. , 1995, Free radical biology & medicine.

[8]  B. Dutrillaux,et al.  Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. , 1997, Anticancer research.

[9]  M. Murphy,et al.  Selective targeting of bioactive compounds to mitochondria. , 1997, Trends in biotechnology.

[10]  S. Hahn,et al.  In vivo radioprotection and effects on blood pressure of the stable free radical nitroxides. , 1998, International journal of radiation oncology, biology, physics.

[11]  A. Haimovitz-Friedman,et al.  Nitroxides Tempol and Tempo Induce Divergent Signal Transduction Pathways in MDA-MB 231 Breast Cancer Cells* , 1998, The Journal of Biological Chemistry.

[12]  S. Hahn,et al.  Evaluation of the hydroxylamine Tempol-H as an in vivo radioprotector. , 2000, Free radical biology & medicine.

[13]  James B. Mitchell,et al.  Nitroxides as radiation protectors. , 2002, Military medicine.

[14]  E. Monti,et al.  Study of in vitro and in vivo effects of the piperidine nitroxide Tempol--a potential new therapeutic agent for gliomas. , 2003, European journal of cancer.

[15]  James B. Mitchell,et al.  Factors influencing nitroxide reduction and cytotoxicity in vitro. , 2004, Antioxidants & redox signaling.

[16]  E. Azzam,et al.  Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: A unifying concept in stress response biology , 2004, Cancer and Metastasis Reviews.

[17]  P. Wipf,et al.  Mitochondrial targeting of selective electron scavengers: synthesis and biological analysis of hemigramicidin-TEMPO conjugates. , 2005, Journal of the American Chemical Society.

[18]  V. Kavsan,et al.  Reduction of the transcription level of the mitochondrial genome in human glioblastoma. , 2005, Cancer letters.

[19]  Qing Zhao,et al.  Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors , 2005, Nature chemical biology.

[20]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[21]  James B. Mitchell,et al.  Therapeutic and clinical applications of nitroxide compounds. , 2007, Antioxidants & redox signaling.

[22]  P. Wipf,et al.  Structural Requirements for Optimized Delivery, Inhibition of Oxidative Stress, and Antiapoptotic Activity of Targeted Nitroxides , 2007, Journal of Pharmacology and Experimental Therapeutics.

[23]  Stephen L. Brown,et al.  Mechanisms of radiation-induced brain toxicity and implications for future clinical trials , 2008, Journal of Neuro-Oncology.

[24]  Qing Zhao,et al.  A Mitochondria-Targeted Triphenylphosphonium-Conjugated Nitroxide Functions as a Radioprotector/Mitigator , 2009, Radiation research.

[25]  James B. Mitchell,et al.  Radioprotectors and Mitigators of Radiation-Induced Normal Tissue Injury , 2010, The oncologist.